Press & Publications
Dermatology Grand Rounds: Diagnostic and Therapeutic Challenges in Nail Disorders
Dermatology Foundation Clark W. Finnerud Award
O: The Oprah Magazine
- "We Looked at 134 Dermatologists in Portland and Picked the Top 6"
- "7 Fingernail Symptoms You Shouldn't Ignore" Dr. Rich's interview from Today.com
- Katu News story "Problem Solvers uncover filthy, dangerous conditions in nail salons"
- Koin News story "What’s the deal with sunscreen?"
- AudioSlides presentation "Apremilast, an oral phosphodiesterase 4 Inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of two phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)"
- article in "A Womens Health" about Manicure and Pedicure Safety
Below is an assortment of publications that were contributed to, or written by, Dr. Phoebe Rich. Dr. Rich is well-known in the dermatology world, especially for her work with Nail Diseases. Check out her publications for more information.
- A long-term safety and efficacy study of trifarotene 50µg g cream in subjects with facial and truncal acne
- A Multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance therapy
- A Randomized, Parallel, Vehicle-Controlled Comparison of Two Erythromycin Benzoyl Peroxide Preparations for Acne Vulgaris
- A triple combination agent in the treatment of melasma
- An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 3.75% for the once-daily treatment of moderate to severe acne vulgaris
- Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) in aqueous gel in moderate of severe acne subpopulations
- Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) in aqueous gel in the treatment of severe acne
- Effect of a single course of isotretinoin therapy on bone mineral density in adolescent patients with severe, recalcitrant, nodular acne
- Hormonal Contraceptives for Acne Management
- Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea
- Subungual melanoma obscured by nail polish
- A slowly enlarging mass on the finger
- Are We Giving Nails Away
- Clinical and Educational Gaps in Dx of Nail Disorders
- Conservative Treatment of Retronychia A Retrospective Study of 25 Patients
- How to Submit a Nail Specimen
- Nail Biopsy Indications and Methods
- Nail changes due to diabetes and other endocrinopathies
- Nail Disorders Diagnosis and Treatment of Infectious, Inflammatory, and Neoplastic Nail Conditions
- Painful Solitary Subungual Nodule
- Promoting and Maintaining or Restoring Healthy Nails Practical Recommendations for Clinicians and Patients
- Update on nail cosmetics
- Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3. randomized, placebo-controlled trial
- Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year
- How To Choose My Treatment
- Improvement in nail psoriasis in the open-label extension of a phase-2 trial of ixekizumab in patients with moderate-to-severe plaque psoriasis
- Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3
- Ixekizumab treatment improves nail psoriasis in patients with moderate-to-severe psoriasis results from the randomized and controlled as well as open-label phases of UNCOVER-3
- Nail Psoriasis
- Nail Psoriasis Severity Index: A Useful Tool for Evaluation of Nail Psoriasis
- The modified Nail Psoriasis Severity Index validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis
- The Nail Psoriasis Severity Index (napsi) 13 years later: validation of an instrument to assess psoriatic nail involvement
- The Nail Psoriasis Severity Index (NAPSI): Validation of an Instrument to Assess Psoriatic Nail Involvement
- The Nail Psoriasis Severity Index (NAPSI) 12 years later: Validation of an instrument to assess psoriatic nail involvement and a review of its use and controversy
- Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1
- A large-scale North American study of fungal isolates from nails the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns
- A new classification system for grading the severity of onychomycosis Onychomycosis Severity Index
- A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis
- Clinical Trial Designs for Topical Antifungal Treatments of Onychomycosis and Implications on Clinical Practice
- Current and Emerging Options in the Treatment of Onychomycosis
- Diagnosis, clinical implications, and complications of onychomycosis
- Effectiveness and Safety of Tavaborole, a Novel Boron-Based Molecule for the Treatment of Onychomycosis: Results from Two Phase 3 Studies
- Efficacy and Safety of Onychomycosis Treatments An Evidence-Based Overview
- Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies
- Efinaconazole 10% solution in the treatment of toenail onychomycosis Two phase III multicenter, randomized, double-blind studies
- Efinaconazole Topical Solution, 10% The Benefits of Treating Onychomycosis Early
- Evaluation of the efficacy and safety of tavaborole topical solution, 5%, in the treatment of onychomycosis of the toenail in adults; a pooled analysis of an 8-week, post-study follow-up from two randomized phase 3 studies
- Fluconazole for the treatment of onychomycosis An update
- Making Strides in Preventing Onychomycosis Recurrence
- Management strategies for onychomycosis in special patient populations
- Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail
- Onchomycosis an overview
- Onychomycosis and tinea pedis in patients with diabetes
- Onychomycosis in special population. Focus on the diabetic
- Onychomycosis information for patients
- Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal
- Prevalence and epidemiology of toenail onychomycosis in diabetic subjects A multicentre survey
- Special patient populations Onychomycosis in the diabetic patient
- The epidemiology, etiology, and pathophysiology of onychomycosis
- Topical treatment of onychomycosis with efinaconazole solution 10%
- Understanding Onychomycosis Treatment mechanisms of action and formulation
- Efficacy and safety of mirikizumab LY3074828 in thetreatment of moderate to severe plaque psoriasis resultsfrom a randomized phase II study
- Esteem poster- EADV and Australian College of Derms
- Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis
- Infectious, Oncologic, and Autoimmune Comorbidities of Psoriasis and Psoriatic Arthritis
- Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3
- Primary efficacy and safety of adalimumab in nail psoriasis from the first 26 weeks of a phase-3, randomized, placebo-controlled trial with subanalysis in patients with and without psoriatic arthritis
- Secukinumab Efficacy Stratified by Body Weight: A Subanalysis From the ERASURE Phase 3 Study in Psoriasis
- Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study
- Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis
- Secukinumab Provides Complete or Almost-complete Psoriasis Clearance in Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of 4 Phase 3 Trials
- Secukinumab shows efficacy in subjects with and without previous exposure to biologic psoriasis therapy subanalysis from the phase 3 FIXTURE study
